Top

Published in:

Open Access 01-11-2020 | Arterial Diseases | Original Research

Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease

Authors: Rocío Salsoso, Talia F. Dalcoquio, Remo H. M. Furtado, André Franci, Carlos J. D. G. Barbosa, Paulo R. R. Genestreti, Celia M. C. Strunz, Viviane Lima, Luciano M. Baracioli, Robert P. Giugliano, Shaun G. Goodman, Paul A. Gurbel, Raul C. Maranhão, Jose C. Nicolau

Published in: Advances in Therapy | Issue 11/2020

Abstract

Introduction

Lipoprotein (a) [Lp(a)] is a risk factor for coronary artery disease (CAD). To the best of our knowledge, this is the first study addressing the relationship between Lp(a) and platelet reactivity in primary and secondary prevention.

Methods

Lp(a) was evaluated in 396 individuals with (82.3%) and without (17.7%) obstructive CAD. The population was divided into two groups according to Lp(a) concentrations with a cutoff value of 50 mg/dL. The primary objective was to evaluate the association between Lp(a) and adenosine diphosphate (ADP)-induced platelet reactivity using the VerifyNow™ P2Y₁₂ assay. Platelet reactivity was also induced by arachidonic acid and collagen–epinephrine (C-EPI) and assessed by Multiplate™, platelet function analyzer™ 100 (PFA-100), and light transmission aggregometry (LTA) assays. Secondary objectives included the assessment of the primary endpoint in individuals with or without CAD.

Results

Overall, 294 (74.2%) individuals had Lp(a) < 50 mg/dL [median (IQR) 13.2 (5.8–27.9) mg/dL] and 102 (25.8%) had Lp(a) ≥ 50 mg/dL [82.5 (67.6–114.5) mg/dL], P < 0.001. Univariate analysis in the entire population revealed no differences in ADP-induced platelet reactivity between individuals with Lp(a) ≥ 50 mg/dL (249.4 ± 43.8 PRU) versus Lp(a) < 50 mg/dL (243.1 ± 52.2 PRU), P = 0.277. Similar findings were present in individuals with (P = 0.228) and without (P = 0.669) CAD, and regardless of the agonist used or method of analysis (all P > 0.05). Finally, multivariable analysis did not show a significant association between ADP-induced platelet reactivity and Lp(a) ≥ 50 mg/dL [adjusted OR = 1.00 [(95% CI 0.99–1.01), P = 0.590].

Conclusion

In individuals with or without CAD, Lp(a) ≥ 50 mg/dL was not associated with higher platelet reactivity.

Available only for authorised users

Borrelli MJ, Youssef A, Boffa MB, Koschinsky ML. New frontiers in Lp(a)-targeted therapies. Trends Pharmacol Sci. 2019;40:212–25. https://doi.org/10.1016/j.tips.2019.01.004.CrossRefPubMed

Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–23. https://doi.org/10.1001/jama.2009.1063.CrossRefPubMed

Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28. https://doi.org/10.1056/NEJMoa0902604.CrossRefPubMed

Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986;256:2540–4. https://doi.org/10.1001/jama.1986.03380180102027.CrossRefPubMed

Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem. 1990;36:20–3.CrossRef

Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082–5. https://doi.org/10.1161/01.cir.102.10.1082.CrossRefPubMed

Nordestgaard BG, Chapman MJ, Ray K, et al. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–53. https://doi.org/10.1093/eurheartj/ehq386.CrossRefPubMedPubMedCentral

Sanchez Muñoz-Torrero JF, Rico-Martín S, Álvarez LR, Aguilar E, Alcalá JN, Monreal M. Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease. Atherosclerosis. 2018;276:10–4. https://doi.org/10.1016/j.atherosclerosis.2018.07.001.CrossRefPubMed

O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–92. https://doi.org/10.1161/CIRCULATIONAHA.118.037184.CrossRefPubMed

10.

O’Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014;63:520–47. https://doi.org/10.1016/j.jacc.2013.09.042.CrossRefPubMed

11.

Zewinger S, Kleber ME, Tragante V, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. Lancet Diabetes Endocrinol. 2017;5:534–43. https://doi.org/10.1016/S2213-8587(17)30096-300107.CrossRefPubMedPubMedCentral

12.

van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611–24. https://doi.org/10.1161/CIRCULATIONAHA.116.020838.CrossRefPubMedPubMedCentral

13.

Ezratty A, Simon DI, Loscalzo J. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry. 1993;32:4628–33. https://doi.org/10.1021/bi00068a021.CrossRefPubMed

14.

Ioka T, Tasaki H, Yashiro A, et al. Association between plasma lipoprotein(a) and endothelial dysfunction in normocholesterolemic and non-diabetic patients with angiographically normal coronary arteries. Circ J. 2002;66:267–71. https://doi.org/10.1253/circj.66.267.CrossRefPubMed

15.

Ouweneel AB, Van Eck M. Lipoproteins as modulators of atherothrombosis: from endothelial function to primary and secondary coagulation. Vascul Pharmacol. 2016;82:1–10. https://doi.org/10.1016/j.vph.2015.10.009.CrossRefPubMed

16.

Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med. 1995;1:256–9. https://doi.org/10.1038/nm0395-256.CrossRefPubMed

17.

Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol. 1998;18:1393–9. https://doi.org/10.1161/01.atv.18.9.1393.CrossRefPubMed

18.

Barre DE. Lipoprotein (a) reduces platelet aggregation via apo(a)-mediated decreases in thromboxane A(2)production. Platelets. 1998;9:93–6. https://doi.org/10.1080/09537109876852.CrossRefPubMed

19.

Gries A, Gries M, Wurm H, et al. Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes. Arterioscler Thromb Vasc Biol. 1996;16:648–55. https://doi.org/10.1161/01.atv.16.5.648.CrossRefPubMed

20.

Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on lipoprotein(a): a call to action. Atherosclerosis. 2019;291:62–70. https://doi.org/10.1016/j.atherosclerosis.2019.10.011.CrossRefPubMed

21.

Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A critical appraisal of aspirin in secondary prevention: is less more? Circulation. 2016;134:1881–906. https://doi.org/10.1161/CIRCULATIONAHA.116.023952.CrossRefPubMed

22.

Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614–23. https://doi.org/10.1016/S0140-6736(13)61170-8.CrossRefPubMed

23.

Séguro F, Bérard E, Bongard V, et al. Real life validation of the European Atherosclerosis Society Consensus Panel lipoprotein(a) threshold of 50 mg/dL. Int J Cardiol. 2016;221:537–8. https://doi.org/10.1016/j.ijcard.2016.07.018.CrossRefPubMed

24.

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143. https://doi.org/10.1161/CIR.0000000000000625.CrossRefPubMed

25.

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:e177–232. https://doi.org/10.1016/j.jacc.2019.03.010.CrossRefPubMed

26.

Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374–92. https://doi.org/10.1016/j.jacl.2019.04.010.CrossRefPubMed

27.

Scharnagl H, Stojakovic T, Dieplinger B, et al. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis. 2019;289:206–13. https://doi.org/10.1016/j.atherosclerosis.2019.08.015.CrossRefPubMed

28.

Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc Interv. 2019;12:1521–37. https://doi.org/10.1016/j.jcin.2019.03.034.CrossRef

29.

Larsen PD, Holley AS, Sasse A, Al-Sinan A, Fairley S, Harding SA. Comparison of Multiplate and VerifyNow platelet function tests in predicting clinical outcome in patients with acute coronary syndromes. Thromb Res. 2017;152:14–9. https://doi.org/10.1016/j.thromres.2017.02.006.CrossRefPubMed

30.

Moenen FCJI, Vries MJA, Nelemans PJ, et al. Screening for platelet function disorders with Multiplate and platelet function analyzer. Platelets. 2019;30:81–7. https://doi.org/10.1080/09537104.2017.1371290.CrossRefPubMed

31.

Jeong YH, Tantry US, Min JH, et al. Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. Int J Cardiol. 2013;168:427–35. https://doi.org/10.1016/j.ijcard.2012.09.132.CrossRefPubMed

32.

Furtado RHM, Giugliano RP, Dalcoquio TF, et al. Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. J Thromb Thrombolysis. 2019;48:217–24. https://doi.org/10.1007/s11239-019-01830-z.CrossRefPubMed

33.

Barbosa CJDG, de Souza Barreiros R, Franci A, et al. Platelet function, coagulation and fibrinolysis in patients with previous coronary and cerebrovascular ischemic events. Clinics (Sao Paulo). 2019;74:e1222. https://doi.org/10.6061/clinics/2019/e1222.CrossRef

34.

Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard B. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. Arterioscler Thromb Vasc Biol. 2020;40:255–66. https://doi.org/10.1161/ATVBAHA.119.312951.CrossRefPubMed

35.

Bittner VA, Szarek M, Aylward PE, et al. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75:133–44. https://doi.org/10.1016/j.jacc.2019.10.057.CrossRefPubMed

36.

Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ Res. 1996;78:615–26. https://doi.org/10.1161/01.res.78.4.615.CrossRefPubMed

37.

Ryan MJ, Emig LL, Hicks GW, et al. Localization of lipoprotein(a) in a monkey model of rapid neointimal growth. Arterioscler Thromb Vasc Biol. 1997;17:181–7. https://doi.org/10.1161/01.atv.17.1.181.J.CrossRefPubMed

38.

Loscalzo J, Vaughan DE. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest. 1987;79:1749–55. https://doi.org/10.1172/JCI113015.CrossRefPubMedPubMedCentral

39.

Schafer AI, Zavoico GB, Loscalzo J, Maas AK. Synergistic inhibition of platelet activation by plasmin and prostaglandin I2. Blood. 1987;69:1504–7. https://doi.org/10.1182/blood.V69.5.1504.CrossRefPubMed

40.

Martínez C, Rivera J, Loyau S, et al. Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost. 2001;85:686–93. https://doi.org/10.1055/s-0037-1615654.CrossRefPubMed

41.

Pedreño J, Fernández R, Cullaré C, Barceló A, Elorza MA, de Castellarnau C. Platelet integrin alpha IIb beta 3 (GPIIb-IIIa) is not implicated in the binding of LDL to intact resting platelets. Arterioscler Thromb Vasc Biol. 1997;17:156–63. https://doi.org/10.1161/01.atv.17.1.156.CrossRefPubMed

42.

Barre DE. Apolipoprotein (a) mediates the lipoprotein (a)-induced biphasic shift in human platelet cyclic AMP. Thromb Res. 2003;112:321–4. https://doi.org/10.1016/j.thromres.2004.01.002.CrossRefPubMed

43.

Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res. 2004;63:130–8. https://doi.org/10.1016/j.cardiores.2004.03.005.CrossRefPubMed

44.

Barre D. Human lipoprotein (a)-induced reduction of platelet aggregation is not mediated by apolipoprotein A’s lysine-binding regions. Front Biosci. 2003;8:s1226–8. https://doi.org/10.1080/09537109876852.CrossRefPubMed

45.

Barre DE, Griscti O, Mizier-Barre KA, Hafez K. Flaxseed oil and lipoprotein(a) significantly increase bleeding time in type 2 diabetes patients in Cape Breton, Nova Scotia. Canada. J Oleo Sci. 2005;6:347–54. https://doi.org/10.5650/jos.54.347.CrossRef

46.

Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195–9.CrossRef

47.

Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol. 1996;16:1568–72. https://doi.org/10.1161/01.atv.16.12.1568.CrossRefPubMed

48.

Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241–9. https://doi.org/10.1161/CIRCULATIONAHA.111.045120.CrossRefPubMed

Title: Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease
Authors: Rocío Salsoso
Talia F. Dalcoquio
Remo H. M. Furtado
André Franci
Carlos J. D. G. Barbosa
Paulo R. R. Genestreti
Celia M. C. Strunz
Viviane Lima
Luciano M. Baracioli
Robert P. Giugliano
Shaun G. Goodman
Paul A. Gurbel
Raul C. Maranhão
Jose C. Nicolau
Publication date: 01-11-2020
Publisher: Springer Healthcare
Keyword: Arterial Diseases
Published in: Advances in Therapy / Issue 11/2020
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI: https://doi.org/10.1007/s12325-020-01483-y

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease

Abstract

Introduction

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2020

PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Mast Cells in Diabetes and Diabetic Wound Healing

Bioequivalence Study Comparing Fixed-Dose Combination of Clopidogrel and Aspirin with Coadministration of Individual Formulations in Chinese Subjects Under Fed Conditions: A Phase I, Open-Label, Randomized, Crossover Study

Responder Profile to Pharmaceutical-Grade Chondroitin Sulfate: An Analysis of the CONCEPT Trial

Fact vs Fallacy: The Anti-Vaccine Discussion Reloaded

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page